{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T14:57:20Z","timestamp":1774882640538,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jpeds.2018.01.008","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T13:13:15Z","timestamp":1524057195000},"page":"191-197.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Rituximab in The Management of Pediatric Steroid-Resistant Nephrotic Syndrome: A Systematic Review"],"prefix":"10.1016","volume":"197","author":[{"given":"Manel","family":"Jellouli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rim","family":"Charfi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bayen","family":"Maalej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdelmajid","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameh","family":"Trabelsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahar","family":"Gargah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2018.01.008_bib0010","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(03)14184-0","article-title":"Nephrotic syndrome in childhood","volume":"362","author":"Eddy","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0015","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1681\/ASN.V85769","article-title":"Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children","volume":"8","author":"Tarshish","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0020","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/ndt\/gfm092","article-title":"Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated","volume":"22","author":"Ehrich","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/kisup.2012.17","article-title":"Steroid-resistant nephrotic syndrome in children","volume":"2","author":"KDIGO","year":"2012","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.jpeds.2018.01.008_bib0030","article-title":"Non-corticosteroid treatment for nephrotic syndrome in children","author":"Hodson","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0035","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00467-012-2393-4","article-title":"Prospective 5-year follow-up cyclosporine treatment in children with steroid resistant nephrosis","volume":"28","author":"Hamasaki","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0040","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/ki.2008.24","article-title":"Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial","volume":"73","author":"Ishikura","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0045","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1681\/ASN.2008070786","article-title":"Role of rituximab therapy in glomerulonephritis","volume":"21","author":"Jayne","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0050","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"NEJM"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0055","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0060","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.2215\/CJN.09421010","article-title":"Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephritic syndrome: a randomized controlled trial","volume":"6","author":"Ravani","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0065","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2013030251","article-title":"Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome","volume":"25","author":"Ruggenenti","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0070","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1056\/NEJMc063706","article-title":"Rituximab in patients with the steroid-resistant nephrotic syndrome","volume":"356","author":"Bagga","year":"2007","journal-title":"NEJM"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0075","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00467-012-2304-8","article-title":"Treatment of steroid-resistant nephrotic syndrome in children: new guidelines from KDIGO","volume":"28","author":"Lombel","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0080","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jebm.12141","article-title":"The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review","volume":"8","author":"Zeng","year":"2015","journal-title":"J Evid Based Med"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0090","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.2215\/CJN.03470410","article-title":"Efficacy and safety of treatment with rituximab for difficult steroid-resistant and dependent nephrotic syndrome: multicentric report","volume":"5","author":"Gulati","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0095","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00467-012-2319-1","article-title":"Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome","volume":"28","author":"Ito","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0100","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00467-014-2765-z","article-title":"Rituximab treatment combined with methylprednisolone pulse therapy and immunosuppressants for childhood steroid-resistant nephrotic syndrome","volume":"29","author":"Kamei","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0105","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/ndt\/gfu267","article-title":"Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome","volume":"30","author":"Sinha","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0110","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1542\/peds.2015-0486","article-title":"Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome","volume":"136","author":"Basu","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0115","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/ped.12804","article-title":"Rituximab and low-dose cyclosporine combination therapy for steroid-resistant focal segmental glomerulosclerosis","volume":"58","author":"Suyama","year":"2016","journal-title":"Pediatr Int"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0120","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00467-009-1376-6","article-title":"Rituximab in refractory nephrotic syndrome","volume":"25","author":"Prytu\u0142a","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0125","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1681\/ASN.2011080775","article-title":"Rituximab in children with resistant idiopathic nephrotic syndrome","volume":"23","author":"Magnasco","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0130","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1203\/01.PDR.0000160446.01907.B1","article-title":"NPHS2 (Podocin) mutations in nephrotic syndrome.Clinical spectrum and fine mechanisms","volume":"57","author":"Caridi","year":"2005","journal-title":"Pediatr Res"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0135","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fped.2016.00039","article-title":"Ethnic differences in childhood nephrotic syndrome","volume":"4","author":"Chanchlani","year":"2016","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0140","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1093\/ndt\/gft532","article-title":"Podocyte-associated gene mutation screening in a heterogeneous cohort of patients with sporadic focal segmental glomerulosclerosis","volume":"29","author":"Laurin","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0145","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actincytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0150","doi-asserted-by":"crossref","DOI":"10.1007\/s00467-017-3780-7","article-title":"Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions, and future options","author":"Kemper","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0155","doi-asserted-by":"crossref","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","article-title":"Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis","volume":"3","author":"Fornoni","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0160","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1681\/ASN.2012040413","article-title":"Rituximab in steroid-resistant nephrotic syndrome in children: a (false) glimmer of hope?","volume":"23","author":"Pradhan","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0165","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/ki.2009.204","article-title":"Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis?","volume":"76","author":"Meyrier","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0170","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00467-008-0794-1","article-title":"Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome: a randomized controlled multicentre trial by the Arbeitsgemeinschaft fur padiatrsche Nephrologie","volume":"23","author":"Olank","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0175","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/153537020422900111","article-title":"The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biologicaleffects","volume":"229","author":"Sharma","year":"2004","journal-title":"Exp Biol Med (Maywood)"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0180","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1365-3083.2001.00950.x","article-title":"Recent progress in the understanding of B-cell functions in autoimmunity","volume":"54","author":"Porakishvili","year":"2001","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0185","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2005-04-1769","article-title":"Generation of biologically active linear and cyclicpeptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor","volume":"107","author":"Perosa","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0190","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1159\/000327611","article-title":"Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study","volume":"33","author":"Cravedi","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0195","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00467-011-1894-x","article-title":"Should we consider MMF therapy after rituximab for nephrotic syndrome?","volume":"26","author":"Filler","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0200","doi-asserted-by":"crossref","first-page":"151","DOI":"10.5414\/CN107092","article-title":"Rituximab in adult patients with immunosuppressive dependent minimal change disease","volume":"76","author":"Hoxha","year":"2011","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0205","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00467-015-3120-8","article-title":"Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome","volume":"30","author":"Counsilman","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0210","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1517\/14740338.4.3.599","article-title":"Reactivation of hepatitis B virus with rituximab","volume":"4","author":"Tsutsumi","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0215","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2007.11.013","article-title":"The emergence ofprogressive multifocal leukoencephalopathy (PML) in rheumatic diseases","volume":"30","author":"Boren","year":"2008","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0220","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","article-title":"Fatal pulmonary fibrosis after rituximab administration","volume":"24","author":"Chaumais","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0225","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00467-013-2485-9","article-title":"Fulminant viralmyocarditis after rituximab therapy in pediatric nephrotic syndrome","volume":"28","author":"Sellier-Leclerc","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0230","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","article-title":"Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases","volume":"23","author":"Guigonis","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpeds.2018.01.008_bib0235","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13052-016-0271-6","article-title":"The efficacy and safety of rituximab in treating childhood nephrotic syndrome: an Italian perspective","volume":"42","author":"Maratea","year":"2016","journal-title":"Ital J Pediatr"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347618300088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347618300088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T03:06:00Z","timestamp":1660964760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347618300088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":46,"alternative-id":["S0022347618300088"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2018.01.008","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab in The Management of Pediatric Steroid-Resistant Nephrotic Syndrome: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2018.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}